ILMN
Next earnings: Jul 30, 2026 · After close
Signal
Bullish Setup3
Price
1
Move+7.13%Strong session
Volume
1
Volume1.5× avgHeavy volume
Technical
1
RSIRSI 55Momentum positive
PRICE
Prev Close
126.74
Open
132.29
Day Range128.06 – 136.63
128.06
136.63
52W Range73.86 – 155.53
73.86
155.53
76% of range
VOLUME & SIZE
Avg Volume
1.8M
FUNDAMENTALS
P/E Ratio
24.7x
EPS (TTM)
Div Yield
No dividend
Beta
1.39
Market-like
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
67% gross margin
Valuation
FAIR
P/E 25x vs ~20x sector
Health
STRONG
CR 1.7 · FCF $6.46/sh
Bullish
Key MetricsTTM
Market Cap$20.63B
Revenue TTM$4.39B
Net Income TTM$853.00M
Free Cash Flow$989.00M
Gross Margin67.1%
Net Margin19.4%
Operating Margin20.9%
Return on Equity32.8%
Return on Assets13.0%
Debt / Equity0.81
Current Ratio1.75
EPS TTM$5.58

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
4 strong2 watch
75/100
Liquidity
1.75Watch
Leverage
0.81Strong
Coverage
12.1xStrong
ROE
32.8%Strong
ROIC
13.5%Watch
Cash
$1.4BStrong
ANALYST COVERAGE24 analysts
HOLD
+6.8%upside to target
L $122.00
Med $145.00consensus
H $170.00
Buy
1250%
Hold
833%
Sell
417%
12 Buy (50%)8 Hold (33%)4 Sell (17%)
Full report →
Stock Health
Composite Score
3 of 4 signals bullish
9/10
Technicals
RSI RangeRSI 55 — Bullish momentum
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusHold
~
LiquidityCurrent Ratio 1.75 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings ReportMay 4, 2026
Tomorrow
DEx-Dividend DateJul 31, 2026
In 89 days
PDividend PaymentAug 15, 2026
In 104 days
Technicals
Technical SetupMIXED
Technicals →

Trend

UptrendGolden Cross · 50D leads 200D by 13.6%

+5.1% vs SMA 50 · +19.3% vs SMA 200

Momentum

RSI54.6
Neutral territory
MACD-1.18
Below zero — bearish pulse · expanding
Market Position
Price Levels
52W High
$155.5+14.5%
Current
$135.8
EMA 50
$126.2-7.1%
EMA 200
$111.5-17.9%
52W Low
$73.86-45.6%
52-Week RangeNear 52-week high
$73.8676th %ile$155.5
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 12 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$4.3B
$4.3B$4.4B
$4.73
±1%
High11
FY2026(current)
$4.6B
$4.5B$4.6B
+6.0%$5.19+9.7%
±2%
High12
FY2027
$4.8B
$4.8B$4.9B
+5.6%$5.89+13.5%
±5%
High12
Range confidence:Tight (high)ModerateWide (low)
🔥Beat 5 consecutive quarters
Earnings HistoryILMN
Last 8Q
+38.1%avg beat
Beat 7 of 8 quartersMissed 1 Estimates rising
+228%
Q3'24
+30%
Q4'24
-7%
Q1'25
+3%
Q2'25
+17%
Q3'25
+15%
Q4'25
+9%
Q1'26
+10%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Analyst Activity
All ratings →
No recent activity
ScotiabankSector Outperform → Sector Perform
Jul 11
DOWNGRADE
HSBCBuy → Hold
Feb 28
DOWNGRADE
CitigroupBuy → Neutral
Dec 11
DOWNGRADE
HSBCBuy
Oct 17
UPGRADE
DaiwaBuy
Aug 16
UPGRADE
WedbushNeutral → Outperform
Aug 14
UPGRADE
Goldman SachsBuy
Aug 14
UPGRADE
BarclaysUnderweight → Equal-Weight
Aug 14
UPGRADE
Cowen & Co.Hold → Buy
Aug 14
UPGRADE
Cowen & Co.Hold → Mixed
Aug 14
UPGRADE
BarclaysUnderweight → Hold
Aug 14
UPGRADE
ScotiabankSector Perform → Sector Outperform
Dec 18
UPGRADE
Insider Activity
SEC Filings →
2 Buys/4 SellsNet Selling
Davies Scott MChief Legal Of…
$155K
Feb 20
SELL
Leckman PatriciaSVP, Chief Peo…
$275K
Feb 18
SELL
Gottlieb ScottDir
$24K
Feb 9
BUY
Davies Scott MChief Legal Of…
$44K
Dec 12
SELL
Wedel Christensen J…SVP, Strategy/…
$71K
Dec 8
SELL
Gottlieb ScottDir
$61K
Nov 3
BUY
Financials

INSTITUTIONAL OWNERSHIP

1
Sumitomo Mitsui Trust Holdings, Inc.
1.0M
2
GUARDCAP ASSET MANAGEMENT Ltd
888K
3
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P.
864K
4
THRIVENT FINANCIAL FOR LUTHERANS
682K
5
Stephens Investment Management Group LLC
389K
6
KEYBANK NATIONAL ASSOCIATION/OH
376K
7
Douglas Lane & Associates, LLC
327K
8
Nuveen, LLC
315K
News & Activity

ILMN News

20 articles · 4h ago

About

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Francis deSouza
Jacob ThaysenCEO, Interim Chief Commercial Officer & Director
Conor Noel McNamaraVice President of Investor Relations
Stephanie CamposPresident